CoChat

FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer

Open access
Royce, Melanie, Osgood, Christy L., Amatya, Anup K., Fiero, Mallorie H., Chang, C.J. George, Ricks, Tiffany K., Shetty, Krithika A., Kraft, Jeffrey, Qiu, Junshan, Song, Pengfei, Charlab, Rosane, Yu, Jingyu, King, Kathryn E., Rastogi, Anshu, Janelsins, Brian, Weinberg, Wendy C., Clouse, Kathleen, Borders-Hemphill, Vicky, Brown, Lindsey, Gomez-Broughton, Candace, Li, Zhong, Nguyen, Thuy Thanh, Qiu, Zhihao, Ly, Anh-Thy, Chang, Suyoung, Gao, Tingting, Tu, Chi-Ming, King-Kallimanis, Bellinda, Pierce, William F., Chiang, Kelly, Lee, Clara, Goldberg, Kirsten B., Leighton, John K., Tang, Shenghui, Pazdur, Richard, Beaver, Julia A., Amiri-Kordestani, Laleh · 2022 · Clinical Cancer Research
Cited by 37

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

On December 16, 2020, the FDA granted regular approval to margetuximab-cmkb (MARGENZA), in combination with chemotherapy, for the treatment of adult patients with HER2-positive (HER2+) metastatic breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. Approval was based on data from SOPHIA, a multicenter, randomized, open-label, active controlled study comparing margetuximab with trastuzumab, in combination with chemotherapy. The primary efficacy endpoint was progression-free survival (PFS) by blinded independent central review. SOPHIA demonstrated a 0.9-month difference in median PFS between the two treatment arms [5.8 vs. 4.9 months, respectively; stratified HR, 0.76 (95% confidence interval: 0.59–0.98; P = 0.0334)]. Overall survival (OS) was immature at the data cut-off date of September 10, 2019. Infusion-related reactions (IRR) are an important safety signal associated with margetuximab plus chemotherapy. In SOPHIA, 13% of patients treated with margetuximab plus chemotherapy reported IRRs, of which 1.5% were grade 3. The most commonly reported adverse drug reactions (>10%) with margetuximab in combination with chemotherapy were fatigue/asthenia, nausea, diarrhea, vomiting, constipation, headache, pyrexia, alopecia, abdominal pain, peripheral neuropathy, arthralgia/myalgia, cough, decreased appetite, dyspnea, IRR, palmar-plantar erythrodysesthesia, and extremity pain. Overall, the favorable risk-benefit profile for margetuximab when added to chemotherapy supported its approval for the intended indication.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-21-3247

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 37

Metadata

Authors
Royce, M., Osgood, C. L., Amatya, A. K., Fiero, M. H., Chang, C. J. G., Ricks, T. K., Shetty, K. A., Kraft, J., Qiu, J., Song, P., Charlab, R., Yu, J., King, K. E., Rastogi, A., Janelsins, B., Weinberg, W. C., Clouse, K., Borders-Hemphill, V., Brown, L., Gomez-Broughton, C., Li, Z., Nguyen, T. T., Qiu, Z., Ly, A.-T., Chang, S., Gao, T., Tu, C.-M., King-Kallimanis, B., Pierce, W. F., Chiang, K., Lee, C., Goldberg, K. B., Leighton, J. K., Tang, S., Pazdur, R., Beaver, J. A., & Amiri-Kordestani, L.
Venue
Clinical Cancer Research
Published
2021-12-16
Volume
28
Issue
8
Pages
1487-1492
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W4200438498
Cited by
37
References
4
FWCI
2.77
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-21-3247
The paper
Royce, M., Osgood, C. L., Amatya, A. K., Fiero, M. H., Chang, C. J. G., Ricks, T. K., Shetty, K. A., Kraft, J., Qiu, J., Song, P., Charlab, R., Yu, J., King, K. E., Rastogi, A., Janelsins, B., Weinberg, W. C., Clouse, K., Borders-Hemphill, V., Brown, L., . . . Amiri-Kordestani, L. (2022). FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-21-3247

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.